IBRX NASDAQ
ImmunityBio, Inc.
1W: -5.0%
1M: -4.1%
3M: -11.0%
YTD: +283.2%
1Y: +166.9%
3Y: +133.8%
5Y: -48.8%
$7.22
-0.52 (-6.72%)
Weekly Expected Move ±11.1%
$6
$7
$8
$9
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
-0.90
Bearish
0 bullish
0 neutral
4 bearish
Articles (24h)
4
Hourly Sentiment (24h)
Articles (4)
IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
IBRX 4-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims – Hagens Berman
TUESDAY INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
0.00
Neutral
8 bullish
1 neutral
8 bearish
Articles (7d)
17
Daily Sentiment (7 Days)
Articles (100)
IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
IBRX 4-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims – Hagens Berman
TUESDAY INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
Why ImmunityBio Stock is Soaring Higher Today
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday
FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer Therapy
ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug
ImmunityBio rises as Anktiva label expansion undergoes FDA review
ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies
ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder Cancer
CLASS ACTION REMINDER: Berger Montague Advises ImmunityBio, Inc. (NASDAQ: IBRX) Investors to Inquire About a Securities Fraud Lawsuit by May 26, 2026
ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th
ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership
ImmunityBio acquiring U.S. rights to Tokyo strain of BCG
DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
IBRX Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages IBRX Investors with Losses to Contact the Firm
IBRX Investor Alert – ImmunityBio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action
IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: Hagens Berman
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
[10-Q] ImmunityBio, Inc. Quarterly Earnings Report - Stock Titan
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Why ImmunityBio Stock Is Surging On Wednesday?
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Soon-Shiong Allegedly Overstated ANKTIVA Efficacy: Levi & Korsinsky
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
ImmunityBio to Report Q1 Earnings: What's in the Cards?
IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: Hagens Berman
Is ImmunityBio, Inc. (IBRX) A Good Stock To Buy Now?
ANKTIVA Strong Demand Propels ImmunityBio, Inc. (IBRX) to Robust Revenue Growth
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
IBRX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ImmunityBio, Inc. Securities Lawsuit - Contact The Gross Law Firm
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
DEADLINE ALERT for SMCI, IBRX, and PINS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit– Hagens Berman
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Made False Drug Claims: Levi & Korsinsky
IBRX Global Rollout: EU, MENA, and Asia Shape 2026-27 Catalysts
Is IBRX Priced for Perfection at Nearly 28x Forward Sales?
IBRX: What Anktiva's Bladder Data Says About 2026 Sales
What Makes ImmunityBio (IBRX) a New Buy Stock
ImmunityBio, Inc. (IBRX) Securities Fraud Class Action Lawsuit Filed; May 26, 2026, Lead Plaintiff Deadline
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
IBRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
IBRX Lawsuit Alleges Misleading Cancer Claims - ImmunityBio Investors Face Losses Following $2B Market Cap Loss – Hagens Berman
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ImmunityBio, Inc. (IBRX) Expands ANKTIVA Access With First Commercial Use in Saudi Arabia
IBRX DEADLINE: The Gross Law Firm Reminds ImmunityBio, Inc. Investors of Upcoming Securities Class Action Deadline
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
SHAREHOLDER ALERT Bernstein Liebhard LLP Securities Class Action Lawsuit Filed Against ImmunityBio, Inc. (IBRX)
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
ROSEN, A LONGSTANDING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
Avis Brings Back The Short Squeeze — Navitas, Beyond Meat Join In
Avis Brings Back The Short Squeeze — Navitas, Beyond Meat Join In
ImmunityBio Stock Rises As ANKTIVA Launches in Saudi Arabia
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)
IBRX Stockholders Have Rights – If You Lost Money Investing in ImmunityBio, Inc. Contact Robbins LLP for Information About Recovering Your Losses
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misled on Drug Efficacy: Levi & Korsinsky
Kessler Topaz Meltzer & Check, LLP - ImmunityBio, Inc. Class Action Lawsuit: Investors Face May 26, 2026, Deadline
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit– Hagens Berman
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
ImmunityBio, Inc. (NASDAQ:IBRX) Receives $14.40 Average Price Target from Analysts
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm
ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
ImmunityBio, Inc. (IBRX) Facing Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman
NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc.
REMINDER: ImmunityBio, Inc. Investors With Significant Losses Must Act By May 26, 2026
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – IBRX
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Lowey Dannenberg Notifies ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results
DEADLINE ALERT for SMCI, IBRX, and PINS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights
IBRX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ImmunityBio, Inc. Securities Lawsuit — The Gross Law Firm
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Why Is ImmunityBio Stock Rallying Thursday?
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline
ImmunityBio reports Q1 results
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit– Hagens Berman
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
ImmunityBio, Inc. Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
IBRX Responds to FDA Warning Over Misleading Cancer Drug Claims
Why ImmunityBio Stock Slumped on Monday